Circovirus sequences associated with piglet weight loss disease (PWD)
View Patent ↗The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-strucutral polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
1. An immunogenic composition comprising (a) a vector that contains and expresses a sequence having at least 90% sequence identity to SEQ ID NO:25, (b) a porcine circovirus type B (PCVB) antigen or epitope thereof, and (c) a pharmaceutically acceptable vehicle or veterinary vehicle.
2. The immunogenic composition of claim 1 , wherein the vector is a viral vector.
3. The immunogenic composition of claim 1 , wherein the vector is a plasmid.
4. The immunogenic composition of claim 1 , wherein the composition induces an immune response in a porcine host against type B porcine circovirus.
5. The immunogenic composition according to claim 1 , further comprising at least one additional antigen and/or at least one nucleic acid selected from nucleic acids capable of expressing at least one additional antigen.
6. The immunogenic composition according to claim 1 , further comprising at least one antigen selected from viral antigens and bacterial antigens and/or at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one member selected from viruses and bacteria.
7. The immunogenic composition according to claim 1 , further comprising at least one member selected from viral toxins, bacterial toxins, viral antigens, and bacterial antigens and/or at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one toxin selected from viral toxins, bacterial toxins, viruses, and bacteria.
8. The immunogenic composition according to claim 7 , wherein the antigen of the at least one bacteria is E. coli.
9. The immunogenic composition according to claim 1 , further comprising at least one vector comprising at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one toxin selected from viral toxins, bacterial toxins, viruses, and bacteria.
10. The immunogenic composition according to claim 9 , wherein the at least one vector is contained by E. coli.
11. The immunogenic composition according to claim 1 , further comprising an adjuvant.
12. A method for inducing an immunological response against a porcine circovirus comprising administering to a porcine the immunogenic composition of claim 1 .
13. An immunogenic composition according to claim 1 , wherein the vector is capable of inducing an immunogenic reaction in a porcine host against a type B porcine circovirus.
14. The immunogenic composition of claim 2 , wherein the vector is a baculovirus vector.
15. The immunogenic composition of claim 1 , wherein the PCVB antigen is encoded by a sequence with at least 90% sequence identity to ORF 2 (SEQ ID NO:25).
16. The immunogenic composition of claim 1 , wherein the PCVB antigen is encoded by a sequence with at least 95% sequence identity to ORF 2 (SEQ ID NO:25).
17. An immunogenic composition comprising (a) a vector that contains and expresses a sequence having at least 95% sequence identity to SEQ ID NO:25, (b) a porcine circovirus type B (PCVB) antigen or epitope thereof, and (c) a pharmaceutically acceptable vehicle or veterinary vehicle.
18. The immunogenic composition of claim 17 , wherein the vector is a viral vector.
19. The immunogenic composition of claim 18 , wherein the viral vector is a baculovirus vector.
20. The immunogenic composition of claim 17 , wherein the vector is a plasmid.
21. The immunogenic composition of claim 17 , wherein the composition induces an immune response in a porcine host against type B porcine circovirus.
22. The immunogenic composition according to claim 17 , further comprising at least one additional antigen and/or at least one nucleic acid selected from nucleic acids capable of expressing at least one additional antigen.
23. The immunogenic composition according to claim 17 , further comprising at least one antigen selected from viral antigens and bacterial antigens and/or at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one member selected from viruses and bacteria.
24. The immunogenic composition according to claim 17 , further comprising at least one member selected from viral toxins, bacterial toxins, viral antigens, and bacterial antigens and/or at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one toxin selected from viral toxins, bacterial toxins, viruses, and bacteria.
25. The immunogenic composition according to claim 24 , wherein the antigen of the at least one bacteria is E. coli.
26. The immunogenic composition according to claim 17 , further comprising at least one vector comprising at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one toxin selected from viral toxins, bacterial toxins, viruses, and bacteria.
27. The immunogenic composition according to claim 26 , wherein the at least one vector is contained by E. coli.
28. The immunogenic composition according to claim 17 , further comprising an adjuvant.
29. A method for inducing an immunological response against a porcine circovirus comprising administering to a porcine the immunogenic composition of claim 17 .
30. An immunogenic composition according to claim 17 , wherein the vector is capable of inducing an immunogenic reaction in a porcine host against a type B porcine circovirus.
31. The immunogenic composition of claim 17 , wherein the PCVB antigen is encoded by a sequence with at least 90% sequence identity to ORF 2 (SEQ ID NO:25).
32. The immunogenic composition of claim 17 , wherein the PCVB antigen is encoded by a sequence with at least 95% sequence identity to ORE 2 (SEQ ID NO: 25).